Revolution Medicines, Inc.
RVMD
शेयरों में रैंक
#579
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
शेयर मूल्य
$196.16
अंतिम समन्वयन: 2026-10-20
मार्केट कैप
$42.04B
बदलाव (1 दिन)
7.69%
बदलाव (1 वर्ष)
266.72%
देश
US
व्यापार Revolution Medicines, Inc. (RVMD)
श्रेणी
Healthcare
Revolution Medicines, Inc. (RVMD) के लिए P/B अनुपात
October 2026 को P/B अनुपात TTM: 15.66
Revolution Medicines, Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/B अनुपात (TTM) 15.66 है। 2023 के अंत में, कंपनी का P/B अनुपात 1.78 था।
Revolution Medicines, Inc. के लिए 2017 से 2026 तक P/B अनुपात का इतिहास
हर वर्ष के अंत में P/B अनुपात
| वर्ष | P/B अनुपात | परिवर्तन |
|---|---|---|
| 2026 (TTM) | 15.66 | 383.31% |
| 2024 | 3.24 | 82.27% |
| 2023 | 1.78 | -36.60% |
| 2022 | 2.80 | -7.84% |
| 2021 | 3.04 | -45.25% |
| 2020 | 5.55 | -19.62% |
| 2019 | 6.91 | -36.63% |
| 2018 | 10.91 | -95.31% |
| 2017 | 232.64 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए P/B अनुपात
| कंपनी | P/B अनुपात | P/B अनुपात में अंतर | देश |
|---|---|---|---|
| 6.251 | -60.08% |
US
|
|
| 13.2547 | -15.36% |
US
|
|
| 4.208 | -73.13% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -60.52% |
NL
|
